|
DE3380848D1
(en)
|
1982-08-04 |
1989-12-21 |
Nat Res Dev |
Molecular cloning of the gene for human anti-haemophilic factor ix
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
ATE74164T1
(de)
|
1985-04-22 |
1992-04-15 |
Genetics Inst |
Herstellung mit hoher leistung des aktivfaktors ix.
|
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
FR2638643B1
(fr)
|
1988-11-09 |
1991-04-12 |
Transgene Sa |
Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
KR940703846A
(ko)
|
1991-12-24 |
1994-12-12 |
비. 린네 파샬 |
갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
CN1127527A
(zh)
|
1993-05-17 |
1996-07-24 |
加利福尼亚大学董事会 |
人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
|
|
JP4285766B2
(ja)
|
1994-03-23 |
2009-06-24 |
オハイオ ユニバーシティ |
緻密にした核酸および細胞へのデリバリ
|
|
GB9408717D0
(en)
|
1994-05-03 |
1994-06-22 |
Biotech & Biolog Scien Res |
DNA sequences
|
|
US6169169B1
(en)
|
1994-05-19 |
2001-01-02 |
Dako A/S |
PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
|
|
DE69841982D1
(de)
|
1997-03-14 |
2010-12-16 |
Philadelphia Children Hospital |
Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
|
|
WO1998054345A1
(en)
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
|
WO1999003496A1
(en)
|
1997-07-21 |
1999-01-28 |
The University Of North Carolina At Chapel Hill |
Factor ix antihemophilic factor with increased clotting activity
|
|
EP1626091B1
(en)
|
2000-06-01 |
2014-07-23 |
University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
NZ522840A
(en)
|
2000-06-01 |
2004-12-24 |
Univ North Carolina |
A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
|
|
US20030143740A1
(en)
|
2001-10-15 |
2003-07-31 |
Christine Wooddell |
Processes for transposase mediated integration into mammalian cells
|
|
US20030108524A1
(en)
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
|
DK2359869T3
(en)
|
2001-12-17 |
2019-04-15 |
Univ Pennsylvania |
Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
|
|
AU2003247962B2
(en)
|
2002-07-18 |
2008-06-12 |
Monsanto Technology Llc |
Methods for using artificial polynucleotides and compositions thereof to reduce transgene silencing
|
|
US7579176B2
(en)
|
2003-10-15 |
2009-08-25 |
Newlight Technologies, Llc |
Method for the production of polyhydroxyalkanoic acid
|
|
EP1804839B1
(en)
|
2004-09-22 |
2012-03-14 |
St. Jude Children's Research Hospital |
Improved expression of factor ix in gene therapy vectors
|
|
ES2465996T3
(es)
|
2006-05-25 |
2014-06-09 |
Sangamo Biosciences, Inc. |
Métodos y composiciones para la inactivación genética
|
|
EP2423305A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
|
EP2848253A1
(en)
|
2006-06-19 |
2015-03-18 |
Asklepios Biopharmaceutical, Inc. |
Modified factor VIII and factor IX genes and vectors for gene therapy
|
|
WO2008133938A2
(en)
|
2007-04-26 |
2008-11-06 |
Sangamo Biosciences, Inc. |
Targeted integration into the ppp1r12c locus
|
|
EP2281050B1
(en)
|
2008-04-14 |
2014-04-02 |
Sangamo BioSciences, Inc. |
Linear donor constructs for targeted integration
|
|
SG191561A1
(en)
|
2008-08-22 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
EP4219547A3
(en)
|
2008-09-15 |
2023-10-18 |
uniQure biopharma B.V. |
Factor ix polypeptide mutant, its uses and a method for its production
|
|
EP3156494B8
(en)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
AU2010235161B2
(en)
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
WO2011011767A1
(en)
|
2009-07-24 |
2011-01-27 |
Sigma-Aldrich Co. |
Method for genome editing
|
|
EP2461821A4
(en)
|
2009-07-31 |
2013-07-03 |
Bayer Healthcare Llc |
MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF
|
|
EP3594333B1
(en)
|
2010-02-08 |
2023-11-01 |
Sangamo Therapeutics, Inc. |
Engineered cleavage half-domains
|
|
EP2534163B1
(en)
|
2010-02-09 |
2015-11-04 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US8771985B2
(en)
|
2010-04-26 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using zinc-finger nucleases
|
|
WO2011146885A2
(en)
|
2010-05-21 |
2011-11-24 |
Virxsys Corporation |
Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing
|
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
|
EP2627665B1
(en)
|
2010-10-12 |
2015-12-16 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia B
|
|
ES2685611T3
(es)
|
2011-02-14 |
2018-10-10 |
The Children's Hospital Of Philadelphia |
Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
|
|
AU2012312260B2
(en)
|
2011-09-21 |
2017-08-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
|
JP6188703B2
(ja)
|
2011-10-27 |
2017-08-30 |
サンガモ セラピューティクス， インコーポレイテッド |
Ｈｐｒｔ遺伝子座を修飾するための方法および組成物
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
AU2013249202B2
(en)
|
2012-04-18 |
2018-08-09 |
The Children's Hospital Of Philadelphia |
Composition and methods for highly efficient gene transfer using AAV capsid variants
|
|
WO2013158309A2
(en)
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
DK3444342T3
(da)
|
2012-07-11 |
2020-08-24 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
EP4357457B1
(en)
|
2012-10-23 |
2024-10-16 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
WO2014089212A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
EP3363902B1
(en)
|
2012-12-06 |
2019-11-27 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
EP2928303A4
(en)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
EP3608308B1
(en)
|
2013-03-08 |
2021-07-21 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
US10604771B2
(en)
|
2013-05-10 |
2020-03-31 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
KR20160019553A
(ko)
|
2013-06-17 |
2016-02-19 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
|
|
EP3011030B1
(en)
|
2013-06-17 |
2023-11-08 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
DK3080274T3
(da)
|
2013-12-09 |
2020-08-31 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til genom-manipulation
|
|
US9962851B2
(en)
|
2013-12-12 |
2018-05-08 |
3M Innovative Properties Company |
Method of making polymeric multilayer films
|
|
ES2895651T3
(es)
|
2013-12-19 |
2022-02-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
|
AU2015218576B2
(en)
|
2014-02-24 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
US20150376586A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
ES3047792T3
(en)
|
2014-07-14 |
2025-12-04 |
Univ California |
Crispr/cas transcriptional modulation
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
CA2969151A1
(en)
|
2014-12-23 |
2016-06-30 |
Syngenta Participations Ag |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
EP3265559B1
(en)
|
2015-03-03 |
2021-01-06 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
WO2016210170A1
(en)
|
2015-06-23 |
2016-12-29 |
The Children's Hospital Of Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
EP3322297B1
(en)
|
2015-07-13 |
2024-12-04 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3159407A1
(en)
|
2015-10-23 |
2017-04-26 |
Silence Therapeutics (London) Ltd |
Guide rnas, methods and uses
|
|
CA3002524A1
(en)
|
2015-10-28 |
2017-05-04 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor viii expression cassettes and methods of use thereof
|
|
CA2999649A1
(en)
|
2015-11-06 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1a
|
|
CN106893739A
(zh)
|
2015-11-17 |
2017-06-27 |
香港中文大学 |
用于靶向基因操作的新方法和系统
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CA3006618A1
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
|
CN109072218B
(zh)
|
2015-12-18 |
2023-04-18 |
国立研究开发法人科学技术振兴机构 |
基因修饰非人生物、卵细胞、受精卵以及目的基因的修饰方法
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
CA3010738A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
|
US11083799B2
(en)
|
2016-03-16 |
2021-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
|
TWI773666B
(zh)
|
2016-03-30 |
2022-08-11 |
美商英特利亞醫療公司 |
Crispr/cas 組分之脂質奈米粒子調配物
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CN105950626B
(zh)
|
2016-06-17 |
2018-09-28 |
新疆畜牧科学院生物技术研究所 |
基于CRISPR/Cas9获得不同毛色绵羊的方法及靶向ASIP基因的sgRNA
|
|
WO2018013932A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
WO2018049009A2
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
EP3516058A1
(en)
|
2016-09-23 |
2019-07-31 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing
|
|
CA3039673A1
(en)
|
2016-10-20 |
2018-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
|
AU2017374044B2
(en)
|
2016-12-08 |
2023-11-30 |
Intellia Therapeutics, Inc. |
Modified guide RNAs
|
|
EP3551169A4
(en)
|
2016-12-09 |
2020-09-09 |
Sangamo Therapeutics, Inc. |
TARGET-SPECIFIC NUCLEASES ADMINISTRATION
|
|
AU2017379073B2
(en)
|
2016-12-22 |
2023-12-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
WO2018126087A1
(en)
|
2016-12-29 |
2018-07-05 |
Applied Stemcell, Inc. |
Gene editing method using virus
|
|
FI3568483T3
(fi)
|
2017-01-10 |
2025-11-21 |
Childrens Medical Res Institute |
Polynukleotideja ja vektoreita siirtogeenien ilmentämiseen
|
|
US20230190958A1
(en)
|
2017-01-13 |
2023-06-22 |
Jichi Medical University |
AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
|
|
WO2018140573A1
(en)
|
2017-01-26 |
2018-08-02 |
Sangamo Therapeutics, Inc. |
B-cell engineering
|
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
EP3622065A1
(en)
|
2017-05-09 |
2020-03-18 |
Emory University |
Clotting factor variants and their use
|
|
CN110945127B
(zh)
|
2017-05-22 |
2024-07-12 |
武田药品工业株式会社 |
用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
|
|
KR102738651B1
(ko)
|
2017-06-15 |
2024-12-05 |
주식회사 툴젠 |
간에서 목적하는 단백질 발현하기 위한 플랫폼
|
|
WO2018232382A1
(en)
|
2017-06-16 |
2018-12-20 |
Applied Stemcell, Inc. |
Gene editing methods with increased knock-in efficiency
|
|
GB2566453B
(en)
|
2017-09-12 |
2021-01-13 |
Univ Of Northumbria At Newcastle |
Impactor for aerosol component collection
|
|
PT3688162T
(pt)
|
2017-09-29 |
2024-04-23 |
Intellia Therapeutics Inc |
Formulações
|
|
AR113154A1
(es)
|
2017-09-29 |
2020-01-29 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para edición del genoma
|
|
US20190247517A1
(en)
|
2017-10-17 |
2019-08-15 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing for hemophilia a
|
|
WO2019087113A1
(en)
|
2017-11-01 |
2019-05-09 |
Novartis Ag |
Synthetic rnas and methods of use
|
|
MA50877A
(fr)
*
|
2017-11-21 |
2020-09-30 |
Bayer Healthcare Llc |
Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
|
|
WO2019122302A1
(en)
|
2017-12-21 |
2019-06-27 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Nucleic acid sequence replacement by nhej
|
|
CA3098458A1
(en)
|
2018-04-29 |
2019-11-07 |
University Of Massachusetts |
Raav-mediated nuclease-associated vector integration (raav-navi)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
WO2019237069A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
WO2019239361A1
(en)
|
2018-06-14 |
2019-12-19 |
Novartis Ag |
Method for sequence insertion using crispr
|
|
CA3103528A1
(en)
|
2018-06-19 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
|
|
CN112585268B
(zh)
|
2018-06-28 |
2025-03-04 |
克里斯珀医疗股份公司 |
通过插入供体多核苷酸用于基因组编辑的组合物和方法
|
|
KR20210049833A
(ko)
*
|
2018-08-10 |
2021-05-06 |
로직바이오 테라퓨틱스, 인크. |
Mma의 치료를 위한 비-붕괴적 유전자 요법
|
|
JP7460643B2
(ja)
|
2018-10-16 |
2024-04-02 |
ブルーアレル， エルエルシー |
遺伝子へのｄｎａの標的化挿入のための方法
|
|
US20200268906A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
AU2019361204A1
(en)
|
2018-10-18 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
|
AU2019361203B2
(en)
|
2018-10-18 |
2026-03-26 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|